Cannabis Bioscience International Holdings (CBIH) Change in Accured Expenses (2023 - 2026)

Cannabis Bioscience International Holdings has disclosed Change in Accured Expenses across 4 years of filings, most recently posting -$25993.0 for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$25993.0, down 274.71% year-over-year; the trailing twelve-month figure through Feb 2026 was $39699.0 (up 151.87% YoY), and the FY2025 annual result was -$65515.0, down 177.27% from the prior year.
• Change in Accured Expenses came in at -$25993.0 for Q1 2026 at Cannabis Bioscience International Holdings, down from $116116.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $116116.0 in Q4 2025 to a low of -$61439.0 in Q2 2024.
• The 4-year median for Change in Accured Expenses is $23023.0 (2023), against an average of $14258.2.
• Across the five-year window, Change in Accured Expenses slumped 351.59% in 2024 and jumped 487.45% in 2025, its largest moves.
• Cannabis Bioscience International Holdings' Change in Accured Expenses stood at $43566.0 in 2023, then sank by 168.79% to -$29969.0 in 2024, then surged by 487.45% to $116116.0 in 2025, then tumbled by 122.39% to -$25993.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$25993.0 (Q1 2026), $116116.0 (Q4 2025), and -$50424.0 (Q2 2025), per Business Quant data.